Nature Communications (Aug 2024)

Multi-omics characterization of the monkeypox virus infection

  • Yiqi Huang,
  • Valter Bergant,
  • Vincent Grass,
  • Quirin Emslander,
  • M. Sabri Hamad,
  • Philipp Hubel,
  • Julia Mergner,
  • Antonio Piras,
  • Karsten Krey,
  • Alexander Henrici,
  • Rupert Öllinger,
  • Yonas M. Tesfamariam,
  • Ilaria Dalla Rosa,
  • Till Bunse,
  • Gerd Sutter,
  • Gregor Ebert,
  • Florian I. Schmidt,
  • Michael Way,
  • Roland Rad,
  • Andrew G. Bowie,
  • Ulrike Protzer,
  • Andreas Pichlmair

DOI
https://doi.org/10.1038/s41467-024-51074-6
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 19

Abstract

Read online

Abstract Multiple omics analyzes of Vaccinia virus (VACV) infection have defined molecular characteristics of poxvirus biology. However, little is known about the monkeypox (mpox) virus (MPXV) in humans, which has a different disease manifestation despite its high sequence similarity to VACV. Here, we perform an in-depth multi-omics analysis of the transcriptome, proteome, and phosphoproteome signatures of MPXV-infected primary human fibroblasts to gain insights into the virus-host interplay. In addition to expected perturbations of immune-related pathways, we uncover regulation of the HIPPO and TGF-β pathways. We identify dynamic phosphorylation of both host and viral proteins, which suggests that MAPKs are key regulators of differential phosphorylation in MPXV-infected cells. Among the viral proteins, we find dynamic phosphorylation of H5 that influenced the binding of H5 to dsDNA. Our extensive dataset highlights signaling events and hotspots perturbed by MPXV, extending the current knowledge on poxviruses. We use integrated pathway analysis and drug-target prediction approaches to identify potential drug targets that affect virus growth. Functionally, we exemplify the utility of this approach by identifying inhibitors of MTOR, CHUK/IKBKB, and splicing factor kinases with potent antiviral efficacy against MPXV and VACV.